Spoken Alpha
NEO
NEOGENOMICS INC
Overview
NeoGenomics provides oncology diagnostic testing and consultative services through a network of laboratories in the United States and United Kingdom.
NEOGENOMICS INC is a Healthcare company operating in Diagnostics & Research with a $2.25B market cap.
Most recent reported earnings: Q3 FY2026 (Oct 26, 2026).
22 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-10-04.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q2 FY2026Earnings2026-07-2824 Q&A exchanges
- Q1 FY2026Earnings2026-04-2819 Q&A exchanges
- Q4 FY2025Earnings2026-02-1730 Q&A exchanges
- Q3 FY2025Earnings2025-10-2817 Q&A exchanges
- Q2 FY2025Earnings2025-07-2928 Q&A exchanges
- Q1 FY2025Earnings2025-04-2934 Q&A exchanges
- Q4 FY2024Earnings2025-02-1830 Q&A exchanges
- Q3 FY2024Earnings2024-11-0538 Q&A exchanges
- Q2 FY2024Earnings2024-07-2932 Q&A exchanges
- Q1 FY2024Earnings2024-04-3016 Q&A exchanges
- Q4 FY2023Earnings2024-02-2018 Q&A exchanges
- Q3 FY2023Earnings2023-11-0628 Q&A exchanges
- Q2 FY2023Earnings2023-08-0831 Q&A exchanges
- Q1 FY2023Earnings2023-05-0837 Q&A exchanges
- Q4 FY2022Earnings2023-02-2330 Q&A exchanges
- Q3 FY2022Earnings2022-11-0817 Q&A exchanges
- Q2 FY2022Earnings2022-08-0922 Q&A exchanges
- Q1 FY2022Earnings2022-04-2719 Q&A exchanges
- Q4 FY2021Earnings2022-02-2322 Q&A exchanges
- Q3 FY2021Earnings2021-11-0429 Q&A exchanges
- Q2 FY2021Earnings2021-08-0622 Q&A exchanges
- Q1 FY2021Earnings2021-05-0513 Q&A exchanges
History
Earnings history
- Q3 FY20262026-10-26EPS— vs $-0.01—Rev— vs ——EODHD
- Q2 FY20262026-07-27EPS$-0.01 vs $-0.06+83.3%Rev$201.7M vs ——EODHD
- Q1 FY20262026-05-04EPS$0.01 vs $0.01-12.3%Rev$186.7M vs ——EODHD
- Q4 FY20252026-02-16EPS$0.06 vs $0.04+50.0%Rev$190.2M vs ——EODHD
- Q3 FY20252025-10-27EPS$0.03 vs $0.02+50.0%Rev$187.8M vs ——EODHD
- Q2 FY20252025-07-28EPS$0.03 vs $0.02+50.0%Rev$181.3M vs ——EODHD
- Q1 FY20252025-04-28EPS$-0.20 vs $-0.01-100.0%Rev$168.0M vs ——EODHD
- Q4 FY20242025-02-17EPS$0.04 vs $0.03+39.9%Rev$172.0M vs ——EODHD
- Q3 FY20242024-11-04EPS$-0.14 vs $0.01-100.0%Rev$167.8M vs ——EODHD
- Q2 FY20242024-07-28EPS$0.03 vs $-0.00+100.0%Rev$164.5M vs ——EODHD
- Q1 FY20242024-04-29EPS$-0.02 vs $-0.05+60.0%Rev$156.2M vs ——EODHD
- Q4 FY20232024-02-19EPS$0.03 vs $-0.03+100.0%Rev$155.6M vs ——EODHD
- Q3 FY20232023-11-05EPS$-0.02 vs $-0.08+75.0%Rev$152.0M vs ——EODHD
- Q2 FY20232023-08-07EPS$-0.05 vs $-0.11+54.5%Rev$146.9M vs ——EODHD
- Q1 FY20232023-05-07EPS$-0.09 vs $-0.15+40.0%Rev$137.2M vs ——EODHD
- Q4 FY20222023-02-22EPS$-0.06 vs $-0.16+62.5%Rev$138.7M vs ——EODHD
- Q3 FY20222022-11-07EPS$-0.14 vs $-0.21+33.3%Rev$128.8M vs ——EODHD
- Q2 FY20222022-08-08EPS$-0.16 vs $-0.23+30.4%Rev$125.1M vs ——EODHD
- Q1 FY20222022-04-26EPS$-0.20 vs $-0.24+16.7%Rev$117.2M vs ——EODHD
- Q4 FY20212022-02-22EPS$-0.14 vs $-0.15+6.7%Rev$125.7M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-10-26 | — | $-0.01 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-07-27 | $-0.01 | $-0.06 | +83.3% | $201.7M | — | — | EODHD |
| Q1 FY2026 | 2026-05-04 | $0.01 | $0.01 | -12.3% | $186.7M | — | — | EODHD |
| Q4 FY2025 | 2026-02-16 | $0.06 | $0.04 | +50.0% | $190.2M | — | — | EODHD |
| Q3 FY2025 | 2025-10-27 | $0.03 | $0.02 | +50.0% | $187.8M | — | — | EODHD |
| Q2 FY2025 | 2025-07-28 | $0.03 | $0.02 | +50.0% | $181.3M | — | — | EODHD |
| Q1 FY2025 | 2025-04-28 | $-0.20 | $-0.01 | -100.0% | $168.0M | — | — | EODHD |
| Q4 FY2024 | 2025-02-17 | $0.04 | $0.03 | +39.9% | $172.0M | — | — | EODHD |
| Q3 FY2024 | 2024-11-04 | $-0.14 | $0.01 | -100.0% | $167.8M | — | — | EODHD |
| Q2 FY2024 | 2024-07-28 | $0.03 | $-0.00 | +100.0% | $164.5M | — | — | EODHD |
| Q1 FY2024 | 2024-04-29 | $-0.02 | $-0.05 | +60.0% | $156.2M | — | — | EODHD |
| Q4 FY2023 | 2024-02-19 | $0.03 | $-0.03 | +100.0% | $155.6M | — | — | EODHD |
| Q3 FY2023 | 2023-11-05 | $-0.02 | $-0.08 | +75.0% | $152.0M | — | — | EODHD |
| Q2 FY2023 | 2023-08-07 | $-0.05 | $-0.11 | +54.5% | $146.9M | — | — | EODHD |
| Q1 FY2023 | 2023-05-07 | $-0.09 | $-0.15 | +40.0% | $137.2M | — | — | EODHD |
| Q4 FY2022 | 2023-02-22 | $-0.06 | $-0.16 | +62.5% | $138.7M | — | — | EODHD |
| Q3 FY2022 | 2022-11-07 | $-0.14 | $-0.21 | +33.3% | $128.8M | — | — | EODHD |
| Q2 FY2022 | 2022-08-08 | $-0.16 | $-0.23 | +30.4% | $125.1M | — | — | EODHD |
| Q1 FY2022 | 2022-04-26 | $-0.20 | $-0.24 | +16.7% | $117.2M | — | — | EODHD |
| Q4 FY2021 | 2022-02-22 | $-0.14 | $-0.15 | +6.7% | $125.7M | — | — | EODHD |
Source: EODHD. NEO reported actuals as published; sparse fields render as —.
Top executives
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for NEO.
$ curl https://api.spokenalpha.com/v1/companies/NEOFAQ
Frequently asked about NEO
Where can I find NEOGENOMICS INC's (NEO) earnings call transcripts?
Spoken Alpha indexes NEO's earnings call transcripts at https://spokenalpha.com/companies/NEO. Each call links to attributed speakers and parsed analyst Q&A. NEOGENOMICS INC's own investor relations page is at https://ir.neogenomics.com/.
When was NEOGENOMICS INC's most recent earnings call?
NEOGENOMICS INC (NEO) held its most recent earnings call on 2026-07-28, covering fiscal Q2 2026.
What sector is NEO in?
NEOGENOMICS INC (NEO) operates in the Healthcare sector (Diagnostics & Research industry).